# A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

> **NCT07358546** · PHASE1 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 32 (estimated)

## Conditions studied

- Non-alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** Efimosfermin alfa

## Key facts

- **NCT ID:** NCT07358546
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-13
- **Primary completion:** 2027-10-13
- **Final completion:** 2027-10-13
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07358546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07358546, "A Study of Efimosfermin Alfa in Adults With Hepatic Impairment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07358546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*